Joe Rogan Experience #2555 - Ron White · Aired Sep 16, 2026
Claim summary · not a verbatim quotation
Taking testosterone increases muscle strength and helps immune system function.
The finding
What the evidence shows
Restoring testosterone in men whose levels are low does have measured benefits, including more lean muscle mass, better sexual function and modest mood improvement in the NIH-funded Testosterone Trials. The immune part is the weak link. Reviews of the research describe androgens including testosterone as generally immunosuppressive, cutting antibody production, T cell proliferation and natural killer cell activity, which is one reason men are more prone to some infections than women. There is no established finding that testosterone therapy makes the immune system work better.
Read the supporting source · pmc.ncbi.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that Taking testosterone increases muscle strength and helps immune system function?
Partly. The claim stretches what the evidence shows. Restoring testosterone in men whose levels are low does have measured benefits, including more lean muscle mass, better sexual function and modest mood improvement in the NIH-funded Testosterone Trials. The immune part is the weak link. It was said on Joe Rogan Experience #2555 - Ron White, aired Sep 16, 2026, at 44:09. We haven't independently confirmed who said it. The supporting source is pmc.ncbi.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.